Caladrius Biosciences and Cend Therapeutics merged, creating Lisata Therapeutics, Inc. at the start of 2022. The company was initially incepted in 1980 as Corniche Group Inc., Phase III Medical Inc.,[4] and NeoStem, Inc., and in 2015, the company changed its identity to Caladrius Biosciences. Whereas Cend Therapeutics was a privately owned biotechnology firm specializing in formulating immuno-oncology treatments. The merger of these two companies results from their shared vision and mission regarding the commercialization and enhancement of advanced treatments and therapies to treat several diseases, such as cancer and other various deteriorating conditions.
Cend Therapeutics and Caladrius Biosciences are considered competent, well respected, and experienced experts in their respective fields; therefore, they consider the merger an innovative way to complement each other’s expertise and benefit the industry on a broader scale. On the one hand, Caladrius Biosciences has shown excellent command and a strong history in the invention of cell-based therapies with a focus on taking advantage of the body’s cells to revive damaged organs and tissues. Their exclusive technologies, consisting of its CD34+ cell treatment platform, have also shown optimistic results regarding initial-stage clinical trials for critical limb ischemia and coronary microvascular dysfunction.
On the contrary, Cend Therapeutics uses the advanced platform of immuno-oncology that utilizes the immune system’s power to attach the cancer cells and eliminate them from the body. In the pre-clinical studies, their potential antibodies and bi-specific T-cell engagers (BiTEs) exhibit practical anti-tumor activities, which created a new future path in the treatment of cancer.
On the grounds of innovative therapeutic treatments, Lisata Therapeutics, Inc. demonstrates significant strengths and advancements. Lisata has demonstrated exciting scientific findings through its clinical trials, lead by the company’s technical expertise, and funded by its financial resources. With the scientifically significant and inspiring merger of Cend Therapeutics and Caladrius Biosciences, the newly formed Lisata Therapeutics, Inc. has the power to change the concept of regenerative medicine and immuno-oncology with its innovative therapies.
Moreover, the creation of Lisata Therapeutics, Inc. initiated more prospects in developing the treatment and therapies for several cancer types and other debilitating illnesses. Not only this, but the merger of Cend Therapeutics and Caladrius Biosciences brings a new light on the dynamic field of biotechnology and pharmaceuticals through their expertise and strengths. Furthermore, their union significantly impacts cancer treatment, especially in the field of immunotherapy, as Immuno-oncology emerges as a fresh way to fight cancer by using the immune system of the body to target and treat the cancer cells specifically. Lisata Therapeutics, Inc. can produce potential cancer immunotherapies that revolutionize cancer treatment and increase positive outcomes by taking advantage of the collaboration of these two companies.
No comments yet